Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

X Xie, T Yu, X Li, N Zhang, LJ Foster, C Peng… - Signal transduction and …, 2023 - nature.com
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Achieving clinical success with BET inhibitors as anti-cancer agents

T Shorstova, WD Foulkes, M Witcher - British journal of cancer, 2021 - nature.com
The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

L Xiao, A Parolia, Y Qiao, P Bawa, S Eyunni, R Mannan… - Nature, 2022 - nature.com
The switch/sucrose non-fermentable (SWI/SNF) complex has a crucial role in chromatin
remodelling and is altered in over 20% of cancers,. Here we developed a proteolysis …

COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics

D Yesudhas, A Srivastava, MM Gromiha - Infection, 2021 - Springer
Purpose The coronavirus outbreak emerged as a severe pandemic, claiming more than 0.8
million lives across the world and raised a major global health concern. We survey the …

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

DE Gordon, GM Jang, M Bouhaddou, J Xu, K Obernier… - Nature, 2020 - nature.com
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has …

Advances in targeting 'undruggable'transcription factors with small molecules

MJ Henley, AN Koehler - Nature Reviews Drug Discovery, 2021 - nature.com
Transcription factors (TFs) represent key biological players in diseases including cancer,
autoimmunity, diabetes and cardiovascular disease. However, outside nuclear receptors …

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

O Gilan, I Rioja, K Knezevic, MJ Bell, MM Yeung… - Science, 2020 - science.org
The two tandem bromodomains of the BET (bromodomain and extraterminal domain)
proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both …

Enhancers in disease: molecular basis and emerging treatment strategies

A Claringbould, JB Zaugg - Trends in molecular medicine, 2021 - cell.com
Enhancers are genomic sequences that play a key role in regulating tissue-specific gene
expression levels. An increasing number of diseases are linked to impaired enhancer …

Fragment-to-lead medicinal chemistry publications in 2020

IJP De Esch, DA Erlanson, W Jahnke… - Journal of medicinal …, 2021 - ACS Publications
Fragment-based drug discovery (FBDD) continues to evolve and make an impact in the
pharmaceutical sciences. We summarize successful fragment-to-lead studies that were …

BET bromodomain inhibitors

MP Schwalm, S Knapp - Current opinion in chemical biology, 2022 - Elsevier
Lysine acetylation creates docking sites for epigenetic reader domains of BET bromodomain
proteins that have emerged as principal regulators of linage specific gene transcription. The …